Carmex Cold Sore Treatment External Analgesic Skin Protectant

Benzocaine, White Petrolatum


Carma Laboratories, Inc.
Human Otc Drug
NDC 10210-0027
Carmex Cold Sore Treatment External Analgesic Skin Protectant also known as Benzocaine, White Petrolatum is a human otc drug labeled by 'Carma Laboratories, Inc.'. National Drug Code (NDC) number for Carmex Cold Sore Treatment External Analgesic Skin Protectant is 10210-0027. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Carmex Cold Sore Treatment External Analgesic Skin Protectant drug includes Benzocaine - 100 mg/g White Petrolatum - 459 mg/g . The currest status of Carmex Cold Sore Treatment External Analgesic Skin Protectant drug is Active.

Drug Information:

Drug NDC: 10210-0027
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Carmex Cold Sore Treatment External Analgesic Skin Protectant
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Benzocaine, White Petrolatum
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Carma Laboratories, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:BENZOCAINE - 100 mg/g
WHITE PETROLATUM - 459 mg/g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH NOT FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 02 Mar, 2017
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 12 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part348
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Carma Laboratories, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:2477289
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0083078004811
UPC stands for Universal Product Code.
NUI:N0000185508
N0000175629
N0000184306
M0000728
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:U3RSY48JW5
B6E5W8RQJ4
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class EPC:Standardized Chemical Allergen [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class PE:Increased Histamine Release [PE]
Cell-mediated Immunity [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class CS:Allergens [CS]
Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient].
Pharmacologic Class:Allergens [CS]
Cell-mediated Immunity [PE]
Increased Histamine Release [PE]
Standardized Chemical Allergen [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
10210-0027-11 TUBE in 1 BLISTER PACK (10210-0027-1) / 2 g in 1 TUBE02 Mar, 2017N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose external analgesic / anti-itch skin protectant

Product Elements:

Carmex cold sore treatment external analgesic skin protectant benzocaine, white petrolatum polyethylene glycol, unspecified hexamethylene diisocyanate/trimethylol hexyllactone crosspolymer mica behenyl olivate ppg-51/smdi copolymer titanium dioxide calcium silicate silicon dioxide ferric oxide red isopropyl titanium triisostearate benzocaine benzocaine white petrolatum benzocaine

Indications and Usage:

Uses for temporary relief of pain and itching associated with symptoms of fever blisters and cold sores helps prevent and protect dry, chapped lips

Warnings:

Warnings for external use only. allergy alert: do not use this product if you have a history of allergy to local anesthetics such as procaine, butacaine, benzocaine, or other "caine" anesthetics stop use and ask a doctor if cold sore symptoms do not improve in 7 days irritation, pain, or redness persists or worsens swelling, rash, or fever develops do not use on • deep or puncture wounds • animal bites • serious burns when using this product keep out of eyes. rinse with water to remove. do not exceed recommended dosage. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.

Do Not Use:

Warnings for external use only. allergy alert: do not use this product if you have a history of allergy to local anesthetics such as procaine, butacaine, benzocaine, or other "caine" anesthetics stop use and ask a doctor if cold sore symptoms do not improve in 7 days irritation, pain, or redness persists or worsens swelling, rash, or fever develops do not use on • deep or puncture wounds • animal bites • serious burns when using this product keep out of eyes. rinse with water to remove. do not exceed recommended dosage. keep out of reach of children. if swallowed, get medical help or contact a poison control center right away.

When Using:

When using this product keep out of eyes. rinse with water to remove. do not exceed recommended dosage.

Dosage and Administration:

Directions adults and children 2 years of age and older apply to affected area (lips) not more than 3 to 4 times daily children 2-12 years of age should be supervised in use of this product children under 2 years of age ask a doctor

Stop Use:

Stop use and ask a doctor if cold sore symptoms do not improve in 7 days irritation, pain, or redness persists or worsens swelling, rash, or fever develops

Package Label Principal Display Panel:

Package labeling: bottle pack


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.